A start-up biotech company with deep scientific roots in New York has garnered $12 million to get to work on a cancer platform. Therasis raised the Series A cash from Tilocor Life Science. The developer has three key scientific founders: Dr. Andrea Califano, director of the Joint Centers for Systems Biology at Columbia University and associate director of the Herbert Irving Comprehensive Cancer Center; Riccardo Dalla-Favera, M.D., director of the Herbert Irving Comprehensive Cancer Center; and Owen A. O'Connor, M.D., Ph.D., presently deputy director of clinical research and cancer treatment at the New York University Cancer Institute. Release